What financial due diligence on a pharmacy actually means
Financial due diligence on a pharmacy does not mean reading the profit-and-loss and checking the number is positive. It means verifying that the NHS income is real and recurring, that the gross margin story is sustainable across the Drug Tariff cycle, and that the accounts are clean before you commit capital. A standard business DD checklist, written for a retail shop or a trade business, misses the NHS-specific risks that sit behind the headline profit.
The sections below follow the workstream a specialist runs: income first, then margin, then VAT, then the balance sheet and staff costs, then regulatory transfer. Each has a pharmacy-specific trap that generic DD does not catch.
For the end-to-end buying process, see the buying a pharmacy UK checklist. For the share-versus-asset structuring question, see share vs asset purchase for a pharmacy. This post owns the DD workstream those two reference.
Verifying the income: FP34 history and the NHSBSA payment lag
A pharmacy's primary income is reimbursement and remuneration under the Community Pharmacy Contractual Framework, not shop takings. The income is contract-driven, not till-driven. That distinction matters because the documents you need to verify it are NHSBSA documents, not till receipts.
The mechanism: prescriptions submitted on the FP34 form each month are processed by the NHSBSA, and payment arrives roughly two months later with an advance on account running in the interim. The ~two-month payment lag creates working-capital timing that does not appear in a conventional P&L without adjustment.
What to request
- At least 24 months of FP34 submission schedules, showing item count, declared value and month submitted.
- The matching NHSBSA payment remittances for each period, to reconcile what was submitted against what was actually paid.
- A reconciliation of the NHSBSA remittance total to the income line in the statutory accounts for each year.
The red flags
- Income on the P&L that cannot be traced to a corresponding NHSBSA remittance.
- Item volumes that spike in the months immediately before the sale period without a clear GP-referral or population explanation.
- Gaps in the FP34 submission history that the seller cannot explain with a dispensing-systems audit trail.
The FP34 cash flow estimator lets you model the working-capital impact of the payment lag on a given monthly item volume. Use it to stress-test how much of the purchase price you need available as working capital, not just as the acquisition consideration.
| Source document | What it proves | Pharmacy-specific check |
|---|---|---|
| FP34 submission schedules | Item volume and declared value submitted each month | Trend consistency; any volume spike near the sale date |
| NHSBSA remittance statements | Actual payment received, including advance on account | Reconciles to P&L income; confirms the ~two-month lag is modelled correctly |
| VAT returns | Output tax and input tax split by period | Zero-rated dispensing turnover consistent with FP34 volume |
| Statutory accounts (two or three years) | Profit, balance sheet, debtors, stock | NHSBSA debtors reconcile to the known ~two-month lag; no unexplained accruals |
| Payroll records | Staff headcount and cost run-rate | Employer NIC at 15% above £5,000 secondary threshold (current rate from April 2025); no off-payroll risk |
The margin story: Category M and Drug Tariff
Gross margin in a pharmacy is not the same as gross margin in a normal retailer. Under the Drug Tariff, reimbursement rates and Category M prices are set centrally and retrospectively adjusted. A margin that looks healthy in the year the seller is marketing reflects the margin for that year's Drug Tariff cycle, not a durable structural margin.
Category M covers a significant proportion of generic dispensing volume. When the NHSBSA recalculates Category M prices retrospectively, the adjustment (clawback or uplift) lands in a later accounting period. This means the margin in year one of your review period may look different from year two or year three because of timing, not because the business changed.
What the analysis needs to cover
- Gross margin as a percentage of dispensing revenue across at least two to three years, not a single year.
- Whether the seller's management accounts strip out Category M adjustments into a separate line so you can see the underlying dispensing margin versus the adjustment timing.
- The proportion of dispensing volume on Category M medicines versus branded or non-Category M lines (a high Category M concentration amplifies the margin volatility).
- Service income from Pharmacy First and similar schemes as a separate, growing revenue line (see the Pharmacy First income accounting post); it has a different margin profile from dispensing and is accounted for separately.
For more on how Drug Tariff changes feed through to the P&L, see drug tariff changes explained and category M clawbacks explained.
The VAT mix check
A community pharmacy is structurally a VAT-mixed business. NHS-dispensed prescription drugs are zero-rated; most OTC retail sales are standard-rated. The mix matters for two reasons: input VAT recoverability and the choice of retail scheme.
Because dispensing turnover is zero-rated, a pharmacy typically reclaims more input VAT than a pure retailer expects. The flip side is that a pharmacy that has applied the wrong VAT retail scheme to split its zero-rated and standard-rated takings may have systematically over- or underpaid VAT, and the liability or credit stays with the company in a share deal.
The VAT retail schemes are the practical mechanic for splitting takings without itemising every sale. The question for DD is whether the scheme in use is appropriate for the actual sales mix, and whether the scheme outputs reconcile to the VAT returns for the period.
What to check
- Which VAT retail scheme the pharmacy uses and whether it is the most appropriate scheme for the dispensing-to-OTC sales ratio.
- Whether VAT returns for the last four years reconcile to the scheme calculations (the HMRC error-correction window for deliberate errors can extend further, but four years is the standard).
- Any private services or Pharmacy First-adjacent private clinic income: these can be exempt or standard-rated rather than zero-rated, and if they have been treated incorrectly the liability is cumulative.
- Partial exemption: it rarely bites in a standard community pharmacy, but check the de minimis limits if the business has any exempt supplies.
In a share deal, any historic VAT underpayment is inherited as a company liability. In an asset deal, a VAT liability stays with the selling company. The structure decision (see share vs asset purchase) affects how VAT risk is allocated at the deal level.
For a broader introduction to pharmacy VAT, see do pharmacies pay VAT and VAT on private services and Pharmacy First.
Balance sheet, stock and staff costs
Three balance-sheet and cost items have pharmacy-specific characteristics that a generic DD checklist treats as routine but are not.
Dispensing stock valuation
Dispensing stock is held at cost under the Drug Tariff reimbursement rates, but those rates move. Stock valued at a price that has since been revised downward by a Category M repricing may be carried at an overstated value. Confirm how the seller values closing stock and whether the valuation is consistent with the current Drug Tariff prices at the balance-sheet date.
Staff costs and the current employer NIC rate
A pharmacy's dispensing operation is labour-intensive: dispensers, counter assistants, pharmacy technicians, and a superintendent pharmacist. The run-rate staff cost you are buying into must be modelled at current rates. Employer NIC is 15% above a £5,000 secondary threshold from April 2025 (the previous rate of 13.8% and threshold of £9,100 are stale). If the seller's management accounts were produced before April 2025 and have not been updated, the staff cost run-rate may be understated.
The Employment Allowance is £10,500, which offsets employer secondary NIC for eligible employers. Check whether the pharmacy is eligible and whether the Allowance has been claimed; it is real cash that reduces the run-rate payroll cost.
Corporation tax position and associated companies
If the seller operates the pharmacy through a company, confirm the corporation tax position. The main rate is 25% on profits over £250,000 and 19% on profits up to £50,000, with Marginal Relief between the two thresholds. Critically, the £50,000 and £250,000 limits are divided by the number of associated companies. A seller who owns several pharmacy companies may have eroded the small-profits rate headroom across their group even if the target company profits look modest in isolation.
In a share purchase, deferred tax liabilities that have not been provided in the accounts, and any pending HMRC enquiries, come with the company. These are matters for the legal and financial DD workstreams to scope jointly.
Use the pharmacy purchase affordability calculator to model how the post-acquisition profit, after the current employer NIC run-rate and corporation tax, supports the finance repayments you are being quoted.
The DD checklist: workstreams at a glance
| Workstream | Documents to request | Why it matters | Pharmacy-specific red flag |
|---|---|---|---|
| Income verification | 24+ months FP34 schedules; NHSBSA remittances | Confirms NHS income is real, recurring and reconcilable to accounts | P&L income not traceable to NHSBSA remittance; item-volume spike near sale |
| Margin story | Three years management accounts; Category M schedule; Drug Tariff mix by volume | Single-year margin is unreliable due to retrospective Drug Tariff adjustments | Only one year of margin data; Category M adjustments not separated in accounts |
| VAT position | VAT returns four years; retail scheme workings; private services income analysis | Wrong retail scheme or mis-classified private services creates inherited liability in a share deal | Scheme not appropriate for actual zero-rated/standard-rated split; private services misclassified |
| Balance sheet and stock | Stock valuation policy; aged creditors and debtors; any HMRC correspondence | Dispensing stock may be overvalued after Drug Tariff repricing; deferred liabilities are inherited in share deals | Stock valued at pre-repricing cost; unexplained accruals or provisions |
| Staff costs | Payroll records; P60s and P11Ds for last two years; Employment Allowance claim history | Run-rate must reflect 15% employer NIC above £5,000 threshold (from April 2025) | Payroll modelled at old 13.8% rate; Employment Allowance not claimed; off-payroll locum risk |
| Regulatory transfer | NHS contract documentation; GPhC premises certificate; superintendent pharmacist appointment | Contract does not pass automatically; GPhC premises registration must be updated | NHS notification not filed as a condition precedent; superintendent post unfilled at completion |
Regulatory and contract DD: the transfer mechanics
The NHS contract is not a standard commercial agreement that automatically assigns on a business sale. Under the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013, a change of ownership requires notification to NHS England, and in some cases approval, before the new owner can operate under the contract.
The practical risk is timing. If the regulatory notification and approval process is not built into the transaction timeline as a condition precedent, a buyer can complete a legal transaction and find they cannot operate the pharmacy under the NHS contract on day one.
Separately, GPhC premises registration must be updated to reflect the new owner. Where the buyer is a company, the company must have a GPhC-registered superintendent pharmacist in post. A sole pharmacist buyer may fulfil that role themselves; a non-pharmacist buyer through a company must have the appointment documented before or at completion.
The content of the regulatory requirements is ownership and registration mechanics only. Clinical and professional matters are outside the scope of this post and outside the services this practice provides.
For the end-to-end process that includes NHS notification steps, see the buying a pharmacy UK checklist.
What a specialist checks before you exchange
The DD workstreams above require source documents that a general business accountant may not know to request, and NHS-specific reconciliations that a pharmacy-specialist checks differently from a standard accounts review. The risk of relying on generic DD is not that it produces a wrong answer from the documents it reviews; it is that it does not request the right documents in the first place.
The areas where specialist pharmacy accounting adds most before exchange:
- Reconciling the NHSBSA remittance trail to the P&L income figure, period by period, rather than accepting the accounts number.
- Normalising the adjusted EBITDA to strip out Category M timing effects and any owner-specific costs that will not transfer, so the purchase price is benchmarked against a number that reflects the business you are buying, not the one marketed.
- Reviewing the VAT retail scheme outputs against the actual sales data, not just the VAT return submissions.
- Modelling the post-acquisition cash-flow cycle using current employer NIC rates and the FP34 payment lag, so the finance repayment schedule is stress-tested against real working-capital timing.
- Identifying any associated-company entanglement that reduces the corporation tax small-profits rate headroom the deal valuation may be assuming.
The buying a pharmacy hub sets out how this practice supports buyers at each stage. The pharmacy purchase accounting service covers the full DD and post-completion accounting workstream.
If you have a purchase price in mind and want to sense-check what the business can afford to borrow and repay at current rates, start with the pharmacy purchase affordability calculator. For the cash-flow impact of the FP34 lag on working capital, use the FP34 cash flow estimator.